Articlenpj biomedical innovations2025
An in vitro hydrogel-based model to study dormancy associated drug resistance in metastatic breast cancer spheroids.
Article in npj biomedical innovations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer remains a leading cause of mortality among women, with brain metastatic breast cancer (BMBC) posing significant challenges due to poor prognosis and therapy resistance. Dormant tumor cells evade treatment, risking late relapse and highlighting the need to study dormancy-associated resistance mechanisms. We employed a biomimetic hyaluronic acid (HA) hydrogel to induce dormancy and suspension culture to promote proliferation, allowing comparison of dormant vs. proliferating BMBC spheroid responses to chemotherapy and targeted therapy. Proliferating spheroids exhibited reduced proliferation and increased apoptosis following treatment, whereas dormant spheroids showed minimal changes, indicating resistance. In proliferating spheroids, the ratio of percentage phosphorylated-ERK/p38 positive cells decreased post-treatment, indicating susceptibility, while dormant spheroids maintained dormancy-associated signaling. Transferring spheroids from HA hydrogel to suspension reversed dormancy, and restored therapy response. Additionally, p38 MAPK inhibition reactivated dormant spheroids, enhancing therapeutic sensitivity. This platform may aid in studying dormancy-associated drug resistance, potentially guiding more effective BMBC therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.